Infliximab treatment for Crohn's disease

Postgraduate Medical Journal

Volumn 77, Issue 909, 2001, Pages 436-440

  Conroy, C A ^a   Cattell, R ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEADACHE; HUMAN; NAUSEA; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034947557     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pmj.77.909.436     Document Type: Article

References (42)

1. Management of Crohn's disease in adults
2. The differential diagniosis of Crohn's disease and ulcerative colitis
3. The gastrointestinal tract
4. Inflammatory bowel disease
5. Inflammatory bowel disease and smoking
6. Experimental models of inflammatory bowel disease
7. On the use of antibiotics in Crohn's disease
8. Mycobacterium paratuberculosis DNA in Crohn's disease tissue
9. Differentiation between Crohn's disease and ulcerative colitis
10. Crohn's disease
11. Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
12. Cytokines in intestinal inflammation: Pathophysiological and clinical considerations
13. Cytokines in inflammatory bowel disease
14. Anti-TNF-alpha antibody treatment for Crohn's disease
15. Construction and initial characterisation of a mouse-human anti-TNF antibody
16. Anti-TNF antibody in Crohn's disease - Status of information, comments and recommendations of an international working group
17. Inflammatory bowel disease: Medical cost algorithms
18. Cytokine-targetted therapies cost-effective in Crohn's disease?
19. Infliximab for the treatment of fistulas in patients with Crohn's disease
20. Tumour necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation of Crohn's ileocolitis
21. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohn's disease: A European multicentre trial
22. Anal complication in Crohn's disease
23. Treatment of fistulas in Crohn's disease with infliximab
24. Successful management of Crohn's disease of the ileoanal pouch with infliximab
25. An evaluation of utility measurement in Crohn's disease
26. Inflammatory bowel disease
27. Evaluation of the Crohn's disease activity index (CDAI) and the dutch index for severity and activity of Crohn's disease. An analysis of the data from the european cooperative Crohn's disease study
28. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
29. A short-term study of chimeric monoclonal antibody Ca2 to tumour necrosis factor α for Crohn's disease
30. Risk of lymphoma in inflammatory bowel disease; a population based estimate
31. Diagnoses of extra-intestinal manifestations and cancers in IBD in large population-based databases
32. Extracolonic malignancies in inflammatory bowel disease
33. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
34. The relationship between infliximab treatment and lymphoma in Crohn's disease
35. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
36. The influence of TNF mAB cA2, on circulating lympohocte populations
37. Anti-tumor necrosis factor alpha therapy of RA
38. Randomised, double-blind, placebo-controlled, multi-centre trial of the engineered human antibody to TNF (CDP571) for the induction and maintenance of clinical improvement in patients with moderate to severely active Crohn's disease
39. Etanercept therapy in rheumatoid arthritis. A randomised controlled trial
40. Thalidomide therapy for patients with refractory Crohn's disaese: An open-label trial
41. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease